QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients
HeartBeam (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. The study will compare synthesized 12-lead ECG readings generated by the company’s patch immediately following exercise stress testing against standard 12-lead ECGs, supporting HeartBeam’s regulatory strategy for a device designed to expand ambulatory cardiac monitoring beyond rhythm assessment into ischemia detection within an established approximately $2 billion patch-based monitoring market. To view the full press release, visit https://ibn.fm/j2bEo About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring…